ConductScience.org, home

Paper40155893

Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review.

Pangprasertkul S and 4 others. BMC Infect Dis, 2025. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review. Papers, record 40155893. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40155893

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review.
PubMed
Journal
BMC Infect Dis
PubMed
Year
2025
PubMed
Publication types
Journal Article, Systematic Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.6, provisional
iCite
Revised in PubMed
2025-07-28
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pangprasertkul SSipang
2Buawangpong NNida
3Pinyopornpanish KKanokporn
4Jiraporncharoen WWichuda
5Angkurawaranon CChaisiri

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
IsoniazidMajor topic
Antitubercular AgentsMajor topic
RifampinMajor topic
Latent TuberculosisMajor topic
TuberculosisMajor topic
Humans
Child
Adolescent
Child, Preschool
Infant
Drug Administration Schedule
Male
Young Adult
Female

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07811518Latent Infection Freshmen Tracking for TuberculosisBackground

Source ClinicalTrials.gov

Download CSV of trials

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128763500Child contact management in high tuberculosis burden countries: A mixed-methods systematic review.PLoS One2017https://conductscience.org/library/papers/28763500PubMed
222717944Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting.Thorax2013https://conductscience.org/library/papers/22717944PubMed
333782057The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ2021https://conductscience.org/library/papers/33782057PubMed
433969644Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review.Pediatr Pulmonol2021https://conductscience.org/library/papers/33969644PubMed
535868608Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection.Int J Infect Dis2022https://conductscience.org/library/papers/35868608PubMed
636815322Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.Clin Infect Dis2023https://conductscience.org/library/papers/36815322PubMed
732199484The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis.Lancet2020https://conductscience.org/library/papers/32199484PubMed
828734517Tuberculosis in Children.Pediatr Clin North Am2017https://conductscience.org/library/papers/28734517PubMed
930029896Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.Tuberculosis (Edinb)2018https://conductscience.org/library/papers/30029896PubMed
1027088582Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection.Pediatr Infect Dis J2016https://conductscience.org/library/papers/27088582PubMed
1137083926Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.Clin Infect Dis2023https://conductscience.org/library/papers/37083926PubMed
1234747900Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.J Chin Med Assoc2021https://conductscience.org/library/papers/34747900PubMed
13393011283HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients.IJTLD Open2024https://conductscience.org/library/papers/39301128PubMed
1428003956Global Burden of Childhood Tuberculosis.Pneumonia (Nathan)2016https://conductscience.org/library/papers/28003956PubMed
1533215187Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.Clin Infect Dis2021https://conductscience.org/library/papers/33215187PubMed
1632703775Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.Eur Respir J2021https://conductscience.org/library/papers/32703775PubMed
1725658592Cost-effectiveness analysis of community active case finding and household contact investigation for tuberculosis case detection in urban Africa.PLoS One2015https://conductscience.org/library/papers/25658592PubMed
1827780211The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.PLoS Med2016https://conductscience.org/library/papers/27780211PubMed
1929910114Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.Am J Prev Med2018https://conductscience.org/library/papers/29910114PubMed
2028575208High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.Clin Infect Dis2017https://conductscience.org/library/papers/28575208PubMed

See all 46 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42952506Factors associated with acceptance of preventive treatment among older adults with latent tuberculosis infection in Huzhou, Zhejiang province: a cross-sectional study.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42952506PubMed
42912081Safety of tuberculosis-preventive treatment in children aged under 5 years: A rapid review.Rev Soc Bras Med Trop2026https://conductscience.org/library/papers/42912081PubMed
42758766
Scaling-up tuberculosis preventive therapy to HIV-negative contacts of bacteriologically confirmed TB cases aged 5 years and above - Lessons from a tuberculosis preventive therapy surge activity in Zambia.
PLOS Glob Public Health2026https://conductscience.org/library/papers/42758766PubMed
42237122Clinical effectiveness of three months once-weekly Isoniazid and Rifapentine regimen for treatment of Latent TB Infection: a systematic review and meta-analysis.BMC Infect Dis2026https://conductscience.org/library/papers/42237122PubMed
41650118Combination interventions to control the tuberculosis epidemic in the Karamoja subregion of Uganda: A modelling analysis.PLOS Glob Public Health2026https://conductscience.org/library/papers/41650118PubMed
41354746Acceptance of preventive therapy for latent tuberculosis infection in Chinese children and adolescents: a systematic review and meta-analysis.Sci Rep2025https://conductscience.org/library/papers/41354746PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40155893

GET https://conductscience.org/api/papers/v1/40155893/references?page=2